



## AMIS Plus Newsletter Nr. 51 - December 2016

Dear AMIS Plus Participants & Sponsors

AMIS Plus looks back on another successful year culminating in its 20<sup>th</sup> anniversary to be celebrated next year as previously announced. We are looking forward to a very exciting session.

Have you saved the date?

9 March 2017, 13:45 - 17:15

Bellevue Palace, Berne
Invitations will be sent out in January



After 20 years of successfully leading the AMIS Plus Steering Committee, Prof. Paul Erne now hands over the reins to Prof. Hans Rickli per January 1<sup>st</sup>, 2017 and wishes him all the very best!



## 5 Best AMIS Plus Hospitals 2016

At the AMIS Plus Steering Committee Meeting it was decided to provide a hit list in the newsletter at the end of each year of the hospitals that not only continuously participate in the AMIS Plus Project but also include all or most of their AMI patients.

We are proud to announce that the winners for 2016 in alphabetical order are:

- Centre hospitalier universitaire vaudois, Lausanne
- Hôpital de La Tour, Meyrin
- Kantonsspital Aarau, Aarau
- Kantonsspital St. Gallen, St. Gallen
- Spital Limmattal, Schlieren

We hope we can motivate more hospitals to strive for a place in the top 5!



## **AMIS Plus Highlight Box**



AMIS Plus took part in the Platelet Inhibition Registry in ACS EvalUation Study (PIRAEUS), which systematically compared available data from European ACS registries focusing on P2Y12 inhibitors. Publications covered methodological considerations as well as patient selection for P2Y12 inhibitor use and outcomes in patients with STEMI and non-STEMI ACS. The results from 84,200 STEMI patients showed that mortality, ischemic events and bleeding rates were lower in the real-world than in those reported in Phase III studies of P2Y12 inhibitors. Newer agents were used in younger and less ill patients who then had fewer complications. Among 84,054 non-STEMI patients there were substantial differences in the use of clopidogrel, prasugrel and ticagrelor subsequently resulting in differences in short- and long-term outcomes. Eur Heart J Cardiovasc Pharmacother 2015; 1:232-44, Eur Heart J Cardiovasc Pharmacother 2016; 2:229-43.

Please find enclosed a paper entitled "Treatment and outcomes of patients with recurrent myocardial infarction: A prospective observational cohort study" by Radovanovic et al. *J Cardiol* 2016; 68:498-503.

We wish you a warm and happy holiday season and a new year filled with peace and happiness.

Yours sincerely

For the Steering Committee:

1. 17

Prof. Paul Erne, MD President For the Data Center:

Dragana Radovanovic, MD Head of the Data Center

AMIS Plus Data Center Hirschengraben 84 CH-8001 Zurich Tel.: +41 (0)44 634 48 30 Fax: +41 (0)44 634 49 86

www.amis-plus.ch info@amis-plus.ch